|
業務類別
|
-- |
|
業務概覽
|
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States. |
| 公司地址
| 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734 |
| 電話號碼
| +1 512 598-0931 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.anebulo.com |
| 員工數量
| 3 |
| Dr. Kenneth C. Cundy,PhD |
Chief Scientific Officer |
美元 380.77K |
29/09/2025 |
| Mr. Richard Anthony Cunningham |
Chief Executive Officer and Director |
美元 332.89K |
29/09/2025 |
| Mr. Daniel V. George |
Chief Financial Officer and Principal Accounting Officer |
美元 147.27K |
29/09/2025 |
|
|
| Mr. Jason M. Aryeh |
Independent Director |
29/09/2025 |
| Mr. Bimal R. Shah |
Independent Director |
29/09/2025 |
| Dr. Joseph F. Lawler, M.D.,PhD |
Chairman of the Board |
29/09/2025 |
| Dr. Nathaniel Calloway, PhD |
Independent Director |
29/09/2025 |
| Mr. Richard Anthony Cunningham |
Chief Executive Officer and Director |
29/09/2025 |
| Mr. Aron R. English |
Independent Director |
29/09/2025 |
| Ms. Areta Kupchyk |
Independent Director |
29/09/2025 |
| Dr. Kenneth Lin, M.D. |
Independent Director |
29/09/2025 |
|
|
|
|
